In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics ... and aminoketone CYP2D6 inhibitor, in Alzheimer’s disease agitation, and results of the ACCORD-2, ADVANCE-2, and long-term safety trials ...

Axsome Therapeutics is moving ahead with plans to submit its Alzheimer’s disease treatment for Food and Drug Administration approval despite mixed results from two new clinical trial readouts.

Axsome plans to submit an NDA for AXS-05 in Alzheimer’s disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from the above controlled and long-term studies.

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as ...

Axsome Therapeutics has announced positive results from its Phase 3 ACCORD-2 trial for AXS-05, a treatment for agitation associated with Alzheimer's disease. The trial met its primary endpoint ...

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.

Axsome plans to submit an NDA for AXS-05 in Alzheimer’s disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from the above controlled and long-term ...